OncoSec Medical Incorporated Quarterly report pursuant to sections 13 or 15(d)

Quarterly report pursuant to sections 13 or 15(d)

Stock-Based Compensation (Details)

Stock-Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	1 Months Ended			3 Months Ended								0 Months Ended
Stock-Based Compensation (Details) (USD $)	Apr. 30, 2013	Apr. 30, 2012	Apr. 30, 2013	Apr. 30, 2012	Apr. 30, 2013 Maximum	Apr. 30, 2012 Maximum	Apr. 30, 2013 Maximum	Apr. 30, 2012 Maximum	Apr. 30, 2013 Minimum	Apr. 30, 2012 Minimum	Apr. 30, 2013 Minimum	Apr. 30, 2012 Minimum	Apr. 30, 2013 Research and development expense	Apr. 30, 2013 Research and development expense	Apr. 30, 2013 General and administrative expense	Apr. 30, 2013 General and administrative expense	May 31, 2011 2011 Plan	May 31, 2011 2011 Plan Maximum	May 31, 2011 2011 Plan Minimum	Apr. 30, 2013 2011 Plan Employees	Oct. 31, 2012 2011 Plan Employees	Oct. 31, 2012 2011 Plan Employees Maximum	Oct. 31, 2012 2011 Plan Employees Minimum	Jan. 31, 2013 2011 Plan Consultant	Oct. 31, 2012 2011 Plan Consultant	Apr. 30, 2013 2011 Plan Director	Apr. 30, 2013 2011 Plan Employees and directors	Apr. 15, 2013 Amended 2011 Plan
Stock-based compensation
Number of additional shares authorized																	5,200,000											3,800,000
Number of shares authorized																												9,000,000
Purchase price of incentive stock options as a percentage of its fair value																			100.00%
Term of stock options																		10 years		10 years	10 years			10 years	3 years	10 years
Provisional percentage of outstanding stock owned by stockholders																			10.00%
Exercise price as a percentage of fair value of common stock for stockholders who own more than 10% of outstanding stock																			110.00%
Options granted to purchase shares			2,200,000																		155,000			30,000	1,200,000		815,000
Vesting period																				3 years		3 years	2 years	1 year		1 year
Exercise price, high end of the range (in dollars per share)																				$ 0.26	$ 0.42
Exercise price, low end of the range (in dollars per share)																				$ 0.23	$ 0.20
Exercise price (in dollars per share)																								$ 0.35	$ 0.18	$ 0.25
Expected volatility, minimum (as a percent)	81.92%	85.96%	81.92%	85.96%
Expected volatility, maximum (as a percent)	97.85%	125.00%	97.85%	125.00%
Risk-free interest rate (as a percent)					1.97%	2.08%	1.97%	2.08%	0.31%	0.82%	0.31%	0.82%
Expected forfeiture rate (as a percent)	0.00%	0.00%	0.00%	0.00%
Expected term					10 years	10 years	10 years	10 years	3 years	5 years	3 years	5 years
Forfeiture rate (as a percent)	0.00%		0.00%
Stock-based compensation expense recognized	$ 90,000		$ 357,000										$ 1,000	$ 32,000	$ 89,000	$ 325,000
Option Shares Outstanding
Balance at the beginning of the period (in shares)			3,175,000
Granted (in shares)			2,200,000																		155,000			30,000	1,200,000		815,000
Exercised (in shares)			(750,000)
Forfeited/Cancelled (in shares)			(273,500)
Balance at the end of the period (in shares)	4,351,500		4,351,500
Weighted-Average Exercise Price
Balance at the beginning of the period (in dollars per share)			$ 0.24
Granted (in dollars per share)			$ 0.21
Exercised (in dollars per share)			$ 0.18
Forfeited/Cancelled (in dollars per share)			$ 0.33
Balance at the end of the period (in dollars per share)	$ 0.23		$ 0.23
Aggregate Intrinsic Value
Balance at the beginning of the period (in dollars)			24,000
Granted (in dollars)			165,000
Exercised (in dollars)			50,000
Balance at the end of the period (in dollars)	$ 275,000		$ 275,000